Optima Medical Provides Update on Annual Filings and Issuance of a Cease Trade Order
TORONTO, ON/ACCESSWIRE/May 9, 2022 / Optima Medical Innovations Corp. OMIC (“OMIC“or the”Company“) announces that pursuant to the Company’s press release dated April 20, 2022, the Company has received notice from the Ontario Securities Commission (the “CSOs“) that the OSC has not accepted the Company’s management cease trade order (the “MCTO“) request and the OSC instead issued a cease trade order (the “CTOThe company requested the MCTO as it anticipated that it would not be able to file its audited annual financial statements, accompanying MD&A and related CEO and CFO certifications for the fiscal year ended December 31, 2021 (the “Annual deposits“) before the prescribed deadline of May 2, 2022. The MCTO would have allowed the Company’s shares to continue trading while applying a cease trade order to the CEO and CFO, but the MCTO did not not been granted.
The OTC issued on or after May 6, 2022 will prohibit trading by any person in any security of the Company, including transactions in the common shares of the Company made through the Canadian Securities Exchange. The Company expects the CTO to remain in place until the annual filings and all continuous disclosure requirements have been filed and the Company receives an order from the OSC revoking the CTO.
The Company’s Board of Directors and its management confirm that they are working with the Company’s auditors to ensure that the Company’s annual filings are completed. The Company will issue a further press release when the annual filings have been made.
The Company confirms as of the date of this press release that there are no insolvency proceedings against it and that there is no other material information relating to the affairs of the Company that has not been generally disclosed.
For more information about the Company
Please visit: Company website
Contact: Ommid Faghani, CEO and Director
About Optima Medical Innovations Corp.
Optima Medical Innovations Corp. is a public company that provides pathways to innovative, science-based health and wellness solutions. OMIC sees the future of medicine in new individualized and targeted treatments. The company is a leader in wellness-focused multidisciplinary pain management. Our goal is to empower patients on their journey to wellness through education and the best medical practices and innovations. Leveraging an extensive network of scientific and medical research, OMIC is an advanced leader in the development of targeted solutions, products and treatments for pain relief, wellness and cancer treatment. Optima Medical Innovations Corp. spans the globe with its multidisciplinary pain clinics, research partners, education and advocacy programs – all working in harmony to bring health and wellness to the world, while creating shareholder value and partners.
Except for statements of historical facts about the Company, certain information contained herein regarding the timing of the filing of the financial statements constitutes forward-looking statements. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Accordingly, there can be no assurance that actual results achieved will be the same, in whole or in part, as those set forth in the forward-looking information. Forward-looking statements are based on the opinions and estimates of management as of the date they are made, and are subject to a variety of risks and uncertainties and other factors that could cause events or actual results differ materially from those projected in the forward-looking statements. – look at the statements. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Except as required by applicable securities laws, the Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change. Readers are cautioned not to place undue reliance on forward-looking statements.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED NOR ACCEPTS RESPONSIBILITY FOR THE SUITABILITY OR ACCURACY OF THIS RELEASE.
THE SOURCE: Optima Medical Innovations Corp.
See the source version on accesswire.com: